PubRank

Britta Weigelt

Author PubWeight™ 72.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006 13.50
2 A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004 8.67
3 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007 4.41
4 Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2010 2.42
5 An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2009 1.93
6 Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 2013 1.83
7 Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010 1.79
8 Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011 1.65
9 Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011 1.45
10 Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 2004 1.44
11 Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012 1.41
12 Road map to metastasis. Nat Med 2003 1.36
13 Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011 1.31
14 Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 2011 1.30
15 Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol 2013 1.28
16 Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010 1.25
17 Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 2002 1.20
18 Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014 1.19
19 Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol 2014 1.19
20 Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2011 1.14
21 Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013 1.14
22 SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol 2014 1.07
23 Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 2012 1.06
24 Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012 1.00
25 Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol 2010 0.99
26 Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol 2010 0.96
27 Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J Pathol 2009 0.95
28 Molecular profiling: moving away from tumor philately. Sci Transl Med 2010 0.95
29 Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol 2010 0.95
30 Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013 0.93
31 PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res 2014 0.89
32 Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. J Pathol 2009 0.89
33 Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 2013 0.88
34 Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology 2012 0.85
35 Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology 2014 0.84
36 Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol 2010 0.81
37 Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer? Histol Histopathol 2013 0.80
38 The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. Int J Gynecol Pathol 2016 0.78
39 Prognostic signatures in breast cancer: correlation does not imply causation. Breast Cancer Res 2012 0.76
40 TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol 2016 0.75
41 Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. Int J Gynecol Pathol 2016 0.75
42 Corrigendum: metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol 2015 0.75